Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live

Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Curran, Desmond, Patterson, Brandon J., Van Oorschot, Desiree, Buck, Philip O., Carrico, Justin, Hicks, Katherine A., Lee, Bruce, Yawn, Barbara P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605828/
https://www.ncbi.nlm.nih.gov/pubmed/30625011
http://dx.doi.org/10.1080/21645515.2018.1558689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605828/
https://www.ncbi.nlm.nih.gov/pubmed/30625011
http://dx.doi.org/10.1080/21645515.2018.1558689

Ejemplares similares